Business Wire

Mentice Appoints New Member to its Board of Directors.

Del

Mentice, the world leading provider of endovascular performance solutions, announced today the appointment of a new independent member to its Board of Directors.

David J. Ballard, M.D., M.S.P.H., Ph.D., F.A.C.P., is a global healthcare executive with proven expertise in improving healthcare value and organizational financial performance while providing international thought leadership. Dr. Ballard was recognized by Becker’s as one of the top 50 experts leading the field of Patient Safety in 2015, 2016, 2017 and 2018 and is the past President of the International Society for Quality in Healthcare. Widely recognized as a global scholar in healthcare quality and value, his two books on healthcare quality leadership received Shingo Awards for their contributions to operational excellence.

“I am excited to join the Mentice board of directors,” says David Ballard, “I am engaging this role because I believe that Mentice technology and solutions can be transformative in our global quest to reduce harm to patients and to make healthcare more affordable.”

Dr. Ballard has served as Chief Quality Officer of Baylor Scott & White Health, the largest healthcare system in Texas (1999-2018). Previously, David served in leadership roles at Emory University (1994-1999), University of Virginia (1991-1994) and Mayo Clinic (1986-1991) after completing degrees in economics, epidemiology and medicine at the University of North Carolina where he was a John Motley Morehead Scholar and training in internal medicine at the Mayo Clinic where he now serves as Healthcare Policy Section Editor for the Mayo Clinic Proceedings.

“It is an honor to have Dr Ballard join our board,” says Lonnie Howell, Chairman of Mentice. “Dr Ballard’s experience from executive positions in large health systems and his global leadership in patient safety will help us drive our expansion with use of our technology for the continuous practice.” Mr. Howell continues, “Our solutions are the established standard for the world’s medical device manufacturers as well as academic medical centers across the world; our next frontier is leveraging the potential of clinical simulation in the continuous practice of improvement in healthcare to reduce harm and the costs of care.”

Mentice is the world leader in virtual reality‐based interventional medical simulation solutions. Our solutions help healthcare professionals with skills acquisition, continuous development and preprocedural planning—leading to improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical industry. Neurovascular, cardiovascular and peripheral interventions are just some of the areas covered by our systems. For more information about Mentice, visit www.mentice.com.

Contact information

Mentice
Hiral Chavda
Marketing Communications Manager
+46 (0) 31 339 94 94
hiral.chavda@mentice.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Corsair Infrastructure Partners Announces Long Term Investments by HarbourVest Partners20.3.2019 14:35:00 CETPressemelding

Corsair Infrastructure Partners (“CIP”), the global infrastructure investment business of Corsair Capital (“Corsair”), today announced that HarbourVest Partners (“HarbourVest”), a leading institutional investor active across multiple asset classes and geographies, has invested in three new CIP-managed funds established to deploy capital in the aviation, port, and road sectors. Earlier this year, CIP’s new funds closed on the acquisitions of shareholdings in three platform companies – the airport developer Vantage Airport Group, the Australian stevedore DP World Australia, and the Spanish toll-road operator Itínere Infraestructuras – from various selling shareholders including Gateway Infrastructure Investments, a legacy CIP-managed vehicle. The investments from HarbourVest come from a long-term pool of institutional capital dedicated to supporting infrastructure equity sponsors like CIP, and will play an important role in the execution of CIP’s growth strategies for all three platforms

Fishawack continues to build best-in-class service offering with Dudnyk acquisition20.3.2019 13:00:00 CETPressemelding

Fishawack, a leading independent healthcare communications specialist, is excited to announce its acquisition of Dudnyk, the Philadelphia-based healthcare communications agency. Dudnyk is an award-winning, full-service agency that specializes in creating insight-driven, authentic brand experiences that unite specialty physicians and their patients. They leverage strategic, scientific, and creative capabilities to serve clients in the biotech, pharmaceutical, and medical device industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190320005204/en/ Dudnyk leadership team includes Christopher Tobias, PhD, President; Laurie Bartolomeo, EVP, Creative Director; Drew Desjardins, EVP, Chief Strategy Officer; Annemarie Armstrong, EVP, Director of Client Services; John Kemble, EVP, Creative Producer. (Photo: Business Wire) Fishawack’s goal is to increase the range of healthcare communications services that it can offer to commerc

ExaGrid Nominated in Six Categories for the 2019 Network Computing Awards20.3.2019 12:00:00 CETPressemelding

ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup, today announced that it has been nominated in six categories for the 2019 Network Computing Awards. ExaGrid has become a finalist for Data Centre Product of the Year, The Return on Investment Award, Hardware Product of the Year, Product of the Year, The Customer Service Award, and Company of the Year. Voting to determine the winner in each category is underway now and closes on April 23. The results will be revealed at an evening award ceremony in London on May 2. ExaGrid’s model EX63000E backup storage appliance with data deduplication is a nominee in four categories. The model provides the largest scale-out system and offers up to a 2PB full backup with an ingest rate of 432TB/hr, which is three times faster than any other backup storage on the market. “We are thrilled to be nominated by IT staff, and recognized by Network Computing, in six prestigious categories this year,” said Bill Andrews, CEO and Pre

Eos Biosciences Issued Patent for New Approach to Shuttle Therapeutics Across the Blood-Brain Barrier to Treat Brain Diseases20.3.2019 11:30:00 CETPressemelding

Eos Biosciences, Inc. (Eos), a nanomedicines company developing an efficient and versatile nanobiologic particle-based platform technology (Eosomes), announced that the U.S. Patent and Trademark Office has granted Eos Biosciences Patent No. 10,183,078, relating to a novel approach of using HER3-targeted Eosomes as a shuttle system for transporting various classes of therapeutics across the blood-brain barrier for treatment of brain disorders, including brain cancer. The patent is owned by Cedars-Sinai Medical Center and is exclusively licensed to Eos Biosciences. Details of the system will be highlighted in an upcoming manuscript from Lali Medina-Kauwe, PhD, Professor, Department of Biomedical Sciences, Cedars-Sinai. Omar Haffar, Ph.D., Founder, President and Chief Executive Officer, commented, “We’re very excited by the issuance of this pivotal patent and look forward to receiving similar approvals in other countries. This patent adds to Eos’ considerable IP portfolio covering the Eos

Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics20.3.2019 10:45:00 CETPressemelding

Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer and Vivet will collaborate on the development of VTX-801, Vivet’s proprietary treatment for Wilson disease. Wilson disease is a devastating, rare, chronic, and potentially life-threatening liver disorder of impaired copper transport that causes serious copper poisoning. In patients with Wilson disease, a monogenetic mutation disables the normal copper biliary excretion pathway leading to excess copper accumulation in the liver and other organs including the central nervous system. Untreated, Wilson disease results in various combinations and severity of hepatic (fibrosis and cirrhosis), neurologic and psychiatric symptoms, which can b

Fintech Company Rimilia Appoints Kevin Kimber as CEO20.3.2019 10:00:00 CETPressemelding

Rimilia, a fintech company helping finance departments simplify the complex, has appointed Kevin Kimber as CEO. The news follows another strong year for Rimilia. In 2018, Rimilia opened offices in Central London and Denver, Colorado in the U.S., and reported significant revenue growth on the previous year. Rimilia was founded in 2008 and its platform, created by finance professionals, uses RPA (robotic process automation) technology to help finance teams fast-track their cash flow by providing clearer information and better control. It has quickly become the industry leader, trusted by a number of global brands from HSBC to DHL and Santander, to provide visibility, improve efficiencies and guarantee cash flow. Rimilia works with any currency, any bank and in any language, and on average delivers 70% cost-savings and an 80% reduction in manual effort to its customers. Kevin joins Rimilia from Eight Roads Ventures (one of Rimilia’s investors), where he was a Venture Partner, advising its